Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis
Paolo Gisondi,Francesco Bellinato,Martina Maurelli,Davide Geat,Alen Zabotti,Dennis McGonagle,Giampiero Girolomoni
DOI: https://doi.org/10.2147/PTT.S323300
2022-08-11
Psoriasis: Targets and Therapy
Abstract:Paolo Gisondi, 1 Francesco Bellinato, 1 Martina Maurelli, 1 Davide Geat, 1 Alen Zabotti, 2 Dennis McGonagle, 3 Giampiero Girolomoni 1 1 Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy; 2 Rheumatology Clinic, Department of Medical and Biological Sciences, University Hospital 'Santa Maria della Misericordia' c/o University of Udine, Udine, Italy; 3 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK Correspondence: Paolo Gisondi, Section of Dermatology and Venereology, Department of Medicine, University of Verona, Piazzale A. Stefani 1, Verona, 37126, Italy, Email Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory arthritis associated with psoriasis, which may manifest with different domains such as dactylitis, enthesitis, synovitis and spondylitis. The estimated prevalence of PsA in patients with psoriasis ranges widely between 6% and 42%. In most cases, PsA is preceded by skin involvement by an average time of 7– 8 years. In the complex patho-mechanisms involved in the transition from psoriasis to PsA, the gut and skin have been proposed as the sites of immune activation triggering or contributing to the development of PsA. In such a transition, a subclinical phase has been identified, characterized by enthesopathy where soluble biomarkers and imaging findings but no clinical symptoms are detectable. Recent studies have provided some evidence that timely treated psoriasis may reduce the risk of developing PsA. Keywords: psoriatic arthritis, psoriasis, therapy, prevention, early intervention, disease modification Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory arthritis associated with cutaneous and/or nail psoriasis. The estimated prevalence of PsA is up to 30% of patients with psoriasis, ranging between 6% and 42% depending on its definition. 1,2 Considering only the studies which applied the Classification Criteria for Psoriatic Arthritis (CASPAR criteria), the prevalence is 23.8% (95% CI, 20.1–27.6%). 3 In approximately 72% of PsA patients, psoriasis precedes the development of arthritis by an average of 7–8 years. 4–6 Hence, the presence of cutaneous or nail psoriasis represents an important risk factor for PsA, and such a latency between the two conditions may have the potential of becoming a precious window of opportunity for preventive interventions. Of note, the annual incidence of PsA among psoriasis patients was found to be constant after the initial diagnosis of psoriasis, varying across the studies from 3.4 to 8 events per 100 000 person-years. 7 Furthermore, the risk of developing PsA was shown to increase with psoriasis severity, being highest in patients with the more severe disease. 8 Patients presenting to Rheumatologists with PsA without prior extensive psoriasis may not have skin involvement to a degree that warrants systemic therapy, whereas more severe cutaneous disease in psoriasis cases that presents to Dermatology naturally places the Dermatologist in a position whereby psoriasis directed systemic therapy can be strategically implemented, not just to treat skin involvement, but to potentially intercept PsA. The initial description of the clinical features of PsA subgroups appeared in 1973. 9 PsA was originally defined by Moll and Wright as a seronegative inflammatory arthritis in the presence of psoriasis presenting with five different types, namely: distal interphalangeal joint arthritis, asymmetrical oligoarthritis, polyarthritis, spondylitis and arthritis mutilans. Although these patterns may change and overlap during the clinical course of the disease, asymmetrical oligoarthritis and polyarthritis are generally considered as the most common. 10 Furthermore, enthesitis is observed in 30–50% and dactylitis in 40–50% although these were not part of the original classification. 10 The diagnosis of PsA is based on clinical and imaging findings in a patient with psoriasis (Figure 1). Among laboratory investigations, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are elevated in 40% while anti–cyclic citrullinated peptide antibodies (ACPA) and/or rheumatoid factor (RF) are negative in 95%. 11 As there are no specific diagnostic tests, diagnosing PsA can be challenging even for skilled physicians, and even more so in the case of early PsA. Indeed, symptoms and signs of prodromal and early PsA may be subtle and fluctuating, as shown by a recent German retrospective analysis that found that unspecific arthritic symptoms (such as acute rheumatism) precede the development of PsA. 12 Similarly, a Bayesian network model found that the musculoskeleta -Abstract Truncated-